文献速递产科

剖宫产术后增加计划性静脉注射酮咯酸及其对阿片类药物使用的影响:一项随机对照试验

Increased Scheduled Intravenous Ketorolac After Cesarean Delivery and Its Effect on Opioid Use: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2023-03-09

这项单中心随机双盲平行组试验将148例剖宫产术后患者随机分为计划性静脉注射酮咯酸组与安慰剂组,比较术后72小时内阿片类药物用量。酮咯酸组中位吗啡毫克当量显著低于安慰剂组,且安慰剂组更易出现疼痛评分大于3分,两组血液学与肾功能指标及满意度相似。

要点

  • 剖宫产术后计划性静脉注射酮咯酸较安慰剂显著降低术后72小时阿片类药物用量。
  • 安慰剂组患者疼痛数字评分大于3分的可能性更高(P=.005)。
  • 两组术后红细胞压积变化、血清肌酐及满意度无显著差异。

核心结论

  • 与安慰剂相比,计划性静脉注射酮咯酸显著降低剖宫产术后阿片类药物使用。

研究设计与样本

  • 单中心、随机、双盲、平行组试验,评估剖宫产术后计划性酮咯酸与安慰剂的疼痛管理效果。
  • 所有接受椎管内麻醉剖宫产的患者术后先接受两剂30 mg静脉注射酮咯酸,随后随机接受四剂30 mg静脉注射酮咯酸或安慰剂,每6小时一次。
  • 额外非甾体抗炎药停用至末次研究药物后6小时;主要结局为术后72小时内总吗啡毫克当量(MME)用量。
  • 每组样本量74例(共148例),在考虑方案不依从后提供80%功效检测MME总体均值差32.4,两组标准差均为68.7。

主要发现

  • 2019年5月至2022年1月筛查245例,随机148例(每组74例),两组患者特征相似。
  • 从到达恢复室至术后72小时的中位(四分位距)MME:酮咯酸组30.0(0.0-67.5)vs 安慰剂组60.0(30.0-112.5),Hodges-Lehmann中位差-30.0(95% CI -45.0至-15.0,P<.001)。
  • 接受安慰剂的参与者更可能出现数字评分量表疼痛评分大于3分(满分10分)(P=.005)。
  • 基线至术后第1天红细胞压积平均±标准差下降:酮咯酸组5.5±2.6% vs 安慰剂组5.4±3.5%(P=.94)。
  • 术后第2天平均±标准差血清肌酐:酮咯酸组0.61±0.06 mg/dL vs 安慰剂组0.62±0.08 mg/dL(P=.26);两组住院疼痛控制与术后护理满意度相似。

关键数值与推荐

  • 计划性静脉注射酮咯酸方案:术后先接受两剂30 mg,随后每6小时四剂30 mg。
  • 主要结局为术后72小时内总MME用量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of scheduled ketorolac in reducing opioid use after cesarean delivery. METHODS: This was a single-center, randomized, double-blind, parallel-group trial to assess pain management after cesarean delivery with scheduled ketorolac compared with placebo. All patients undergoing cesarean delivery with neuraxial anesthesia received two doses of 30 mg intravenous ketorolac postoperatively and then were randomized to receive four doses of 30 mg of intravenous ketorolac or placebo every 6 hours. Additional nonsteroidal anti-inflammatory drugs were held until 6 hours after the last study dose. The primary outcome was total morphine milligram equivalents (MME) used in the first 72 postoperative hours. Secondary outcomes included the number of patients who used no opioid postoperatively, postoperative pain scores, postoperative change in hematocrit and serum creatinine, and postoperative satisfaction with inpatient care and pain management. A sample size of 74 per group (n=148) provided 80% power to detect a population mean difference in MME of 32.4, with an SD for both groups of 68.7 after accounting for protocol noncompliance. RESULTS: From May 2019 to January 2022, 245 patients were screened and 148 patients were randomized (74 per group). Patient characteristics were similar between groups. The median (quartile 1-3) MME from arrival in the recovery room until postoperative hour 72 was 30.0 (0.0-67.5) for the ketorolac group and 60.0 (30.0-112.5) for the placebo group (Hodges-Lehmann median difference -30.0, 95% CI -45.0 to -15.0, P <.001). In addition, participants who received placebo were more likely to have numeric rating scale pain scores higher than 3 out of 10 ( P= .005). The mean±SD decrease from baseline hematocrit to postoperative day 1 was 5.5±2.6% for the ketorolac group and 5.4±3.5% for the placebo group ( P =.94). The mean±SD postoperative day 2 creatinine was 0.61±0.06 mg/dL in the ketorolac group and 0.62±0.08 mg/dL in the placebo group ( P =.26). Participant satisfaction with inpatient pain control and postoperative care was similar between groups. CONCLUSION: Compared with placebo, scheduled intravenous ketorolac significantly decreased opioid use after cesarean delivery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT03678675.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hostage J, Kolettis D, Sverdlov D, et al. Increased Scheduled Intravenous Ketorolac After Cesarean Delivery and Its Effect on Opioid Use: A Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 36897140. doi:10.1097/AOG.0000000000005120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。